Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Subunit vaccines are safer and more stable than live vaccines although they have the disadvantage of eliciting poor immune response. To develop a subunit vaccine, an effective delivery system targeting the key elements of the protective immune response is a prerequisite. In this study, oxidized carbon nanospheres (OCNs) were used as a subunit vaccine delivery system and tuberculosis (TB) was chosen as a model disease. TB is among the deadliest infectious diseases worldwide and an effective vaccine is urgently needed. The ability of OCNs to deliver recombinant Mycobacterium tuberculosis (Mtb) proteins, Ag85B and HspX, into bone marrow derived macrophages (BMDMs) and dendritic cells (BMDCs) was investigated. For immunization, OCNs were mixed with the two TB antigens as well as the adjuvant monophosphoryl lipid A (MPL). The protective efficacy was analyzed in vaccinated mice by aerosol Mtb challenge with a virulent strain of Mtb and the bacterial burdens were measured. The results showed that OCNs are highly effective in delivering Mtb proteins into the cytosol of BMDMs and BMDCs. Upon immunization, this vaccine formula induced robust Th1 immune response characterized by cytokine profiles from restimulated splenocytes and specific antibody titer. More importantly, enhanced cytotoxic CD8+ T cell activation was observed. However, it did not reduce the bacteria burden in the lung and spleen from the aerosol Mtb challenge. Taken together, OCNs are highly effective in delivering subunit protein vaccine and induce robust Th1 and CD8+ T cell response. This vaccine delivery system is suitable for application in settings where cell-mediated immune response is needed.
Abstract
Subunit vaccines are safer and more stable than live vaccines although they have the disadvantage of eliciting poor immune response. To develop a subunit vaccine, an effective delivery system targeting the key elements of the protective immune response is a prerequisite. In this study, oxidized carbon nanospheres (OCNs) were used as a subunit vaccine delivery system and tuberculosis (TB) was chosen as a model disease. TB is among the deadliest infectious diseases worldwide and an effective vaccine is urgently needed. The ability of OCNs to deliver recombinant Mycobacterium tuberculosis (Mtb) proteins, Ag85B and HspX, into bone marrow derived macrophages (BMDMs) and dendritic cells (BMDCs) was investigated. For immunization, OCNs were mixed with the two TB antigens as well as the adjuvant monophosphoryl lipid A (MPL). The protective efficacy was analyzed in vaccinated mice by aerosol Mtb challenge with a virulent strain of Mtb and the bacterial burdens were measured. The results showed that OCNs are highly effective in delivering Mtb proteins into the cytosol of BMDMs and BMDCs. Upon immunization, this vaccine formula induced robust Th1 immune response characterized by cytokine profiles from restimulated splenocytes and specific antibody titer. More importantly, enhanced cytotoxic CD8+ T cell activation was observed. However, it did not reduce the bacteria burden in the lung and spleen from the aerosol Mtb challenge. Taken together, OCNs are highly effective in delivering subunit protein vaccine and induce robust Th1 and CD8+ T cell response. This vaccine delivery system is suitable for application in settings where cell-mediated immune response is needed.
참고문헌 (40)
- Moreno-Mendieta SA, "Adjuvants in tuberculosis vaccine development", FEMS Immmunol. Med. Microbiol, 58, pp.75~84 (2010)
- Andersen P, "The success and failure of BCG-implications for a novel tuberculosis vaccine", Nat. Rev. Microbiol, 3, pp.656~662 (2005)
- Nunes-Alves C, "In search of a new paradigm for protective immunity to TB", Nat. Rev. Microbiol, 12, pp.289~299 (2014)
- Ottenhoff TH, "Vaccines against tuberculosis: where are we and where do we need to go?", PLoS Path, 8, pp.e1002607~ (2012)
- Fehres CM, "Understanding the biology of antigen cross-presentation for the design of vaccines against cancer", Front. Immunol, 5, pp.149~ (2014)
- Kasturi SP, "Cross-presentation: avoiding trafficking chaos?", Nat, Immunol, 9, pp.461~463 (2008)
- Joshi VB, "Biodegradable particles as vaccine delivery systems : size matters", AAPS J, 15, pp.85~94 (2013)
- Smith DM, "Applications of nanotechnology for immunology", Nat. Rev. Immunol, 13, pp.592~605 (2013)
- Gregory AE, "Vaccine delivery using nanoparticles", Front. Cell. Infect. Microbiol, 3, pp.13~ (2013)
- Couvreur PV, C, "Nanotechnology : Intelligent design to treat complex disease", Pharm. Res, 23, pp.1417~1450 (2006)
- Demento SL, "Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype", Biomaterials, 33, pp.4957~4964 (2012)
- van Dissel JT, "Ag85B–ESAT-6 adjuvanted with IC31promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers", Vaccine, 28, pp.3571~3581 (2010)
- Leleux J, "Micro and nanoparticle-based delivery systems for vaccine immunotherapy : an immunological and materials perspective", Adv. Healthc Mater, 2, pp.72~94 (2013)
- Shen H, "Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles", Immunology, 117, pp.78~88 (2006)
- Hirosue S, "Antigen delivery to dendritic cells by poly(propylene sulfide)nanoparticles with disulfide conjugated peptides : Cross-presentation and T cell activation", Vaccine, 28, pp.7897~7906 (2010)
- Khademi F, "Potential of polymeric particles as future vaccine delivery systems", adjuvants for parenteral and non-parenteral immunization against tuberculosis : A systematic review, 2018, pp.21, 116~123
- Arayachukeat S, "Clusters of carbon nanospheres derived from graphene oxide", ACS Appl. Mat. Inter, 4, pp.6808~6815 (2012)
- Arayachukiat S, "Bringing macromolecules into cells and evading endosomes by oxidized carbon nanoparticles", Nano Lett, 15, pp.3370~3376 (2015)
- Mata-Haro V, "The vaccine adjuvant monophosphoryl lipid a as a TRIF-biased agonist of TLR4", Science, 316, pp.1628~1632 (2007)
- Yuan Y, "T he 1 6-kDa α-crystallin(Acr)protein of Mycobacterium tuberculosis is required for growth in macrophages", Proc. Natl. Acad. Sci. USA, 95, pp.9578~9583 (1998)
- Belisle JT, "Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis", Science, 276, pp.1420~1422 (1997)
- Boonyatecha N, "Involvement of notch signaling pathway in regulating IL-12 expression via c-Rel in activated macrophages", Mol. Immunol, 51, pp.255~262 (2012)
- Nguyen TNY, "Cell wall mannan of Candida krusei mediates dendritic cell apoptosis and orchestrates Th17 polarization via TLR-2", MyD88-dependent pathway, 2018, pp.8, 17123~
- Fletcher HA, "TB vaccine development and the End TB Strategy : importance and current status", Trans. R. Soc. Trop. Med. Hyg, 110, pp.212~218 (2016)
- Grode L, "Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin", J. Clin. Invest, 115, pp.2472~2479 (2005)
- Hoft DF, "A new recombinant BCG vaccine safely induces significantly enhanced TB-specific immunity in human volunteers", J. Infect. Dis, 198, pp.1491~1501 (2008)
- Nieuwenhuizen NE, "Next-generation vaccines based on Bacille Calmette-Guerin", Front Immunol, 9, pp.121~ (2018)
- Winau F, "Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis", Immunity, 24, pp.105~117 (2006)
- Desel C, "Recombinant BCG Delta ureC hly+induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses", J. Infect. Dis, 204, pp.1573~1584 (2011)
- Casella CR, "Putting endotoxin to work for us : monophosphoryl lipid A as a safe and effective vaccine adjuvant", Cell Mol. Life Sci, 65, pp.3231~3240 (2008)
- Awasthi S, "Toll-Like receptor-4 modulation for cancer immunotherapy", Front Immunol, 5, pp.328~ (2014)
- Neeland MR, "The Lymphatic immune response induced by the adjuvant AS01: a comparison of intramuscular and subcutaneous immunization routes", J. Immunol, 197, pp.2704~ (2016)
- Leleux J, "Micro and nanoparticle-based delivery systems for vaccine immunotherapy : an immunological and materials perspective", Adv. Healthc. Mater, 2, pp.72~94 (2013)
- Carlétti D, "A single dose of a DNA vaccine encoding apa coencapsulated with 6, 6’-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice", Clin. Vaccine immunol, 20, pp.1162~1169 (2013)
- Ha S-J, "Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination", Infect. Immun, 74, pp.4954~4959 (2006)
- Crotty S, "T follicular helper cell differentiation, function, and roles in disease", Immunity, 41, pp.529~542 (2014)
- Olsen AW, "Protective effect of a tuberculosis subunit vaccine based on a fusion of Antigen 85B and ESAT-6 in the aerosol guinea pig model", Infect. Immun, 72, pp.6148~6150 (2004)
- Doherty TM, "Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis", J. Infect. Dis, 190, pp.2146~2153 (2004)
- Niu H, "Multistage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice", PLoS One, 10, pp.e0130641~ (2015)
- Aagaard C, "A multistage tuberculosis vaccine that confers efficient protection before and after exposure", Nat. Med, 17, pp.189~194 (2011)